{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:08Z","timestamp":1792612268522,"version":"4.5.0"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:p>Inflammatory bowel disease remains a chronic condition in which a substantial proportion of patients fail to achieve durable clinical remission despite advances in therapy. Although the treatment landscape has expanded to include biologics and small-molecule agents, contemporary management is increasingly focused on altering the course of the disease rather than relying on symptom control alone. Central to this shift is the recognition that intestinal reparative therapy, defined by objective endpoints such as endoscopic and histologic healing, is strongly associated with improved long-term outcomes. Emerging mechanistic data highlight epithelial repair pathways as actionable therapeutic targets. Among these, glucagon-like peptides secreted by intestinal enteroendocrine cells have gained attention for their roles in epithelial integrity and inflammation modulation. This review synthesizes basic science and translational evidence supporting glucagon-like peptide-1, glucagon-like peptide-2, and dipeptidyl peptidase-IV inhibition as emerging therapeutic concepts in inflammatory bowel disease. Furthermore, it provides a critical appraisal of recent human observational data, distinguishing metabolic benefits from intrinsic disease-modifying effects, and outlines the practical clinical friction points and prospective trials necessary to validate these pathways in future treatment paradigms.<\/jats:p>","DOI":"10.3389\/fgstr.2026.1790420","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T04:17:13Z","timestamp":1779077833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity"],"prefix":"10.3389","volume":"5","author":[{"given":"Joseph J.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Scripps Clinic","place":["La Jolla, CA, United States"]},{"name":"Naval Medical Center San Diego, Department of Surgery","place":["San Diego, CA, United States"]},{"name":"Department of Molecular & Cellular Biology, The Scripps Research Institute","place":["La Jolla, CA, United States"]},{"name":"Department of Immunology and Microbiology, The Scripps Research Institute","place":["La Jolla, CA, United States"]},{"name":"Calibr-Skaggs, The Scripps Research Institute","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratikiran","family":"Bajgain","sequence":"additional","affiliation":[{"name":"Department of Molecular & Cellular Biology, The Scripps Research Institute","place":["La Jolla, CA, United States"]},{"name":"Department of Immunology and Microbiology, The Scripps Research Institute","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Lightner","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Scripps Clinic","place":["La Jolla, CA, United States"]},{"name":"Department of Molecular & Cellular Biology, The Scripps Research Institute","place":["La Jolla, CA, United States"]},{"name":"Department of Immunology and Microbiology, The Scripps Research Institute","place":["La Jolla, CA, United States"]},{"name":"Calibr-Skaggs, The Scripps Research Institute","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41586-019-0992-y","article-title":"Colonic epithelial cell diversity in health and inflammatory bowel disease","volume":"567","author":"Parikh","year":"2019","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2025-2","article-title":"Pathway paradigms revealed from the genetics of inflammatory bowel disease","volume":"578","author":"Graham","year":"2020","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.618918","article-title":"Advanced understanding of monogenic inflammatory bowel disease","volume":"8","author":"Nambu","year":"2021","journal-title":"Front Pediatr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/ceg.s303688","article-title":"Patients\u2019 experiences and challenges in living with inflammatory bowel disease: a qualitative approach","volume":"14","author":"Popov","year":"2021","journal-title":"Clin Exp Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","article-title":"Immunological pathogenesis of inflammatory bowel disease","volume":"16","author":"Lee","year":"2018","journal-title":"Intestinal Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)60751-x","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2017.03.007","article-title":"Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease","volume":"4","author":"Martini","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i5.1165","article-title":"Intestinal barrier in inflammatory bowel disease","volume":"20","author":"Antoni","year":"2014","journal-title":"World J Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2017.1343143","article-title":"The intestinal barrier: a fundamental role in health and disease","volume":"11","author":"Vancamelbeke","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s470520","article-title":"Restore intestinal barrier integrity: an approach for inflammatory bowel disease therapy","volume":"17","author":"Kong","year":"2024","journal-title":"J Inflammation Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00390-X","article-title":"The intestinal barrier: a pivotal role in health, inflammation, and cancer","volume":"10","author":"Neurath","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-019-01698-z","article-title":"Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives","volume":"392","author":"Zatorski","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.trsl.2021.06.001","article-title":"Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier","volume":"236","author":"Liu","year":"2021","journal-title":"Transl Research"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29163954","article-title":"Current treatments, emerging therapeutics, and natural remedies for inflammatory bowel disease","volume":"29","author":"Yeshi","year":"2024","journal-title":"Molecules"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08122-w","article-title":"Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics","volume":"68","author":"Dunleavy","year":"2023","journal-title":"Digestive Dis Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298186","article-title":"Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci170771","article-title":"Claudin-2 protects against colitis-associated cancer by promoting colitis-associated mucosal healing","volume":"133","author":"Ahmad","year":"2023","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01250-7","article-title":"Notoginsenoside R1 promotes Lgr5+ stem cell and epithelium renovation in colitis mice via activating Wnt\/\u03b2-catenin signaling","volume":"45","author":"Yu","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.02.025","article-title":"Future directions in inflammatory bowel disease management","volume":"8","author":"D'Haens","year":"2014","journal-title":"J Crohn's Colitis"},{"key":"B24","unstructured":"Lee\n              J\n            \n          \n          Immune cell distribution in the intestinal crypts under homeostasis and inflammatory bowel disease. BioRender\n          \n          2026"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(18)32858-8","article-title":"Anglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid sequence of the cDNA","volume":"258","author":"Lund","year":"1983","journal-title":"J Biol Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.689678","article-title":"Proglucagon-derived peptides as therapeutics","volume":"12","author":"Lafferty","year":"2021","journal-title":"Front Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.2.345","article-title":"Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem","volume":"79","author":"Lund","year":"1982","journal-title":"Proc Natl Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/en.143.8.3152","article-title":"Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells","volume":"143","author":"Abraham","year":"2002","journal-title":"Endocrinology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-08-0085","article-title":"Mechanisms underlying proglucagon gene expression","volume":"198","author":"Jin","year":"2008","journal-title":"J Endocrinol"},{"key":"B31","unstructured":"Lee\n              JJ\n            \n          \n          Post-translational processing of proglucagon mRNA with PCs. BioRender\n          \n          2026"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3109\/00365529609009147","article-title":"Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day","volume":"31","author":"Orskov","year":"1996","journal-title":"Scandinavian J Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9040383","article-title":"GLP-1 and intestinal diseases","volume":"9","author":"Hunt","year":"2021","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/bf01316798","article-title":"Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man","volume":"38","author":"Wettergren","year":"1993","journal-title":"Digestive Dis Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.1.6","article-title":"International Union of Pharmacology. XXXV. The glucagon receptor family","volume":"55","author":"Mayo","year":"2003","journal-title":"Pharmacol Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/en.136.10.4629","article-title":"Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties","volume":"136","author":"Wheeler","year":"1995","journal-title":"Endocrinology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-201x.1996.33260000.x","article-title":"Signal transduction and desensitization of the glucagon-like peptide-1 receptor","volume":"157","author":"Thorens","year":"1996","journal-title":"Acta Physiol Scand"},{"key":"B40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.12993","article-title":"cAMP signalling in insulin and glucagon secretion","volume":"19","author":"Tengholm","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1051","article-title":"PKA enhances the acute insulin response leading to the restoration of glucose control","volume":"64","author":"Kaihara","year":"2015","journal-title":"Diabetes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-201x.1996.42256000.x","article-title":"Distribution of GLP-1 and PACAP receptors in human tissues","volume":"157","author":"Wei","year":"1996","journal-title":"Acta Physiol Scand"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/en.134.5.2156","article-title":"Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse","volume":"134","author":"Campos","year":"1994","journal-title":"Endocrinology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198024","article-title":"Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons","volume":"13","author":"Anand","year":"2018","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet (London England)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/bf00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2012.08.016","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice","volume":"179","author":"Kissow","year":"2012","journal-title":"Regul Pept"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13808","article-title":"Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats","volume":"33","author":"Nozu","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0000000000000847","article-title":"GLP-1 induces barrier protective expression in Brunner's glands and regulates colonic inflammation","volume":"22","author":"Bang-Berthelsen","year":"2016","journal-title":"Inflammatory Bowel Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.10.008","article-title":"Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion","volume":"21","author":"Lebrun","year":"2017","journal-title":"Cell Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1146\/annurev.nutr.26.061505.111223","article-title":"Glucagon-like peptide-2","volume":"26","author":"Estall","year":"2006","journal-title":"Annu Rev Nutr"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2000.278.1.e134","article-title":"Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats","volume":"278","author":"Tavares","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.8.6717","article-title":"In vivo and in vitro degradation of glucagon-like peptide-2 in humans","volume":"85","author":"Hartmann","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.03.006","article-title":"Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway","volume":"6","author":"Yusta","year":"2017","journal-title":"Mol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i26.4117","article-title":"Gut hormones, and short bowel syndrome: The enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation","volume":"12","author":"Martin","year":"2006","journal-title":"World J Gastroenterol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.4.1569","article-title":"Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2","volume":"96","author":"Munroe","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1021\/bi000497p","article-title":"Structural determinants for activity of glucagon-like peptide-2","volume":"39","author":"DaCambra","year":"2000","journal-title":"Biochemistry"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-00442-0","article-title":"A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor","volume":"30","author":"Sun","year":"2020","journal-title":"Cell Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1210\/me.2004-0196","article-title":"The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1\/2 activation through divergent signaling pathways","volume":"19","author":"Koehler","year":"2005","journal-title":"Mol Endocrinol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-0309","article-title":"Glucagonlike peptide-2 receptor activation in the rat intestinal mucosa","volume":"144","author":"Walsh","year":"2003","journal-title":"Endocrinology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.16489","article-title":"Enteroendocrine localization of GLP-2 receptor expression in humans and rodents","volume":"119","author":"Yusta","year":"2000","journal-title":"Gastroenterology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2004.07.009","article-title":"GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors","volume":"124","author":"\u00d8rskov","year":"2005","journal-title":"Regul Pept"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00111.2011","article-title":"The \u201ccryptic\u201d mechanism of action of glucagon-like peptide-2","volume":"301","author":"Rowland","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0918","article-title":"Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts","volume":"152","author":"Leen","year":"2011","journal-title":"Endocrinology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.05.055","article-title":"The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice","volume":"131","author":"Dub\u00e9","year":"2006","journal-title":"Gastroenterology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00149.2007","article-title":"Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators","volume":"293","author":"Dub\u00e9","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.07.027","article-title":"The protective and antiinflammatory effects of a modified glucagon-like peptide-2 dimer in inflammatory bowel disease","volume":"155","author":"Gu","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/ijms17020190","article-title":"GLP-2 attenuates LPS-induced inflammation in BV-2 cells by inhibiting ERK1\/2, JNK1\/2 and NF-kB signaling pathways","volume":"17","author":"Li","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn's disease complicated by strictures: a systematic review","volume":"62","author":"Rieder","year":"2013","journal-title":"Gut"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s229","article-title":"DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors","author":"Dicker","year":"2011","journal-title":"Diabetes Care"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front Endocrinol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2017.07.001","article-title":"Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease","author":"Akoumianakis","year":"2017","journal-title":"Vasc Pharmacol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13059-024-03325-4","article-title":"Gut microbiota DPP4-like enzymes are increased in type-2 diabetes and contribute to incretin inactivation","volume":"25","author":"Olivares","year":"2024","journal-title":"Genome Biol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.09.012","article-title":"An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease","volume":"226","author":"Zhong","year":"2013","journal-title":"Atherosclerosis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvx086","article-title":"New insights into the role of adipose tissue in thrombosis","volume":"113","author":"Vilahur","year":"2017","journal-title":"Cardiovasc Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvx093","article-title":"The microcirculation: a key player in obesity-associated cardiovascular disease","volume":"113","author":"Sorop","year":"2017","journal-title":"Cardiovasc Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(24)01827-4","article-title":"Sa1950 impact of GLP1 agonists on inflammatory biomarkers in patients with inflammatory bowel disease","volume":"166","author":"Sehgal","year":"2024","journal-title":"Gastroenterology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2016.08.004","article-title":"GLP-1 nanomedicine alleviates gut inflammation","volume":"13","author":"Anbazhagan","year":"2017","journal-title":"Nanomedicine: Nanotechnology Biol Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1577","article-title":"GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s152835","article-title":"Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate\/nuclear factor-kB pathway in vitro","volume":"11","author":"Al-Dwairi","year":"2018","journal-title":"J Inflammation Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13784","article-title":"GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells","volume":"172","author":"Sun","year":"2024","journal-title":"Immunology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12876-023-02716-4","article-title":"Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats","volume":"23","author":"Skarbaliene","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13361","article-title":"The pivotal relation between glucagon\u2010like peptides, NFkB and inflammatory bowel disease","volume":"47","author":"Azmy","year":"2020","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e0198046","DOI":"10.1371\/journal.pone.0198046","article-title":"Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice","volume":"13","author":"Hytting-Andreasen","year":"2018","journal-title":"PloS One"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2023.09.014","article-title":"A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment","volume":"32","author":"Marotti","year":"2024","journal-title":"Bioact Mater"},{"key":"B92","unstructured":"Lee\n              JJ\n            \n          \n          Proposed mechanistic framework distinguishing indirect metabolic pathways from direct epithelial reparative programs of GLP-1 and GLP-2 in inflammatory bowel disease. BioRender\n          \n          2026"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09344-w","article-title":"Glucagon-like peptide-1 receptor agonist therapy does not increase gastrointestinal adverse events in patients with inflammatory bowel disease","volume":"70","author":"Weng","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003208","article-title":"Safety and effectiveness of glucagon-like peptide-1 receptor agonists in inflammatory bowel disease","volume":"120","author":"Anderson","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08720-2","article-title":"Efficacy and safety of GLP-1 agonists on metabolic parameters in non-diabetic patients with inflammatory bowel disease","volume":"69","author":"St-Pierre","year":"2024","journal-title":"Dig Dis Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-08964-6","article-title":"Tolerability and effectiveness of glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease","volume":"70","author":"Clarke","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18138","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"60","author":"Desai","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae250","article-title":"GLP-1 receptor agonists confer no increased rates of IBD exacerbation among patients with IBD","volume":"31","author":"Levine","year":"2025","journal-title":"Inflammatory Bowel Dis"},{"key":"B101","doi-asserted-by":"publisher","first-page":"jjae160","DOI":"10.1093\/ecco-jcc\/jjae160","article-title":"GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: a report from the Epi-IIRN","volume":"19","author":"Gorelik","year":"2025","journal-title":"J Crohn's Colitis"},{"key":"B102","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","volume":"37","author":"Villumsen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B103","doi-asserted-by":"publisher","first-page":"jjaf167","DOI":"10.1093\/ecco-jcc\/jjaf167","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential","volume":"19","author":"Colwill","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(25)03695-9","article-title":"Mo1908: Glucagon-like peptide-1 receptor agonist use in patients with perianal fistulizing Crohn's disease is well tolerated and leads to weight loss and clinical improvement in fistula activity","volume":"169","author":"Bergenholtz","year":"2025","journal-title":"Gastroenterology"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1038\/nutd.2012.29","article-title":"Visceral and subcutaneous adipose tissue from lean women respond differently to lipopolysaccharide-induced alteration of inflammation and glyceroneogenesis","volume":"2","author":"Vatier","year":"2012","journal-title":"Nutr Diabetes"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.22541\/au.171134196.67057249\/v1","article-title":"Subcutaneous adipose tissue: Implications in dermatological diseases and beyond","volume":"79","author":"Ziadlou","year":"2024","journal-title":"Allergy"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e01544","DOI":"10.14309\/crj.0000000000001544","article-title":"Dramatic changes in thiopurine metabolite levels in a patient with inflammatory bowel disease treated with tirzepatide for weight loss","volume":"11","author":"Klein","year":"2024","journal-title":"ACG Case Rep J"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1610368","article-title":"GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation","volume":"16","author":"Migliorisi","year":"2025","journal-title":"Front Immunol"},{"key":"B111","unstructured":"A phase 3b, randomized, multicenter, controlled study of mirikizumab and placebo or mirikizumab concomitantly administered with tirzepatide in adult participants with moderately to severely active ulcerative colitis and obesity or overweight\n          \n          \n            \n              Eli\n              L\n            \n          \n          Bethesda, MD\n          U.S. National Library of Medicine\n          ClinicalTrials.gov\n          \n          2025"},{"key":"B112","unstructured":"A randomized clinical trial to determine the effect of dual glucose-dependent insulinotropic polypeptide (GIP)\/GLP-1 receptor agonist-mediated weight loss and diet on crohn's disease clinical response: a pilot study\n          \n          \n            \n              Damas\n              OM\n            \n          \n          Bethesda, MD\n          U.S. National Library of Medicine\n          ClinicalTrials.gov\n          \n          2025"},{"key":"B113","unstructured":"Moving beyond inflammation as a therapeutic target for crohn's disease\n          \n          \n          Bethesda, MD\n          U.S. National Library of Medicine\n          ClinicalTrials.gov\n          \n          2025"},{"key":"B114","unstructured":"An open-label extension trial to evaluate the long-term safety of apraglutide in short bowel syndrome\n          \n          \n          Bethesda, MD\n          U.S. National Library of Medicine\n          ClinicalTrials.gov\n          \n          2025"},{"key":"B115","unstructured":"A phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with short bowel syndrome (SBS)\n          \n          \n          Bethesda, MD\n          U.S. National Library of Medicine\n          ClinicalTrials.gov\n          \n          2025"},{"key":"B116","unstructured":"A double-blind phase 3 extension trial assessing the long term safety and efficacy of glepaglutide in patients with short bowel syndrome (SBS)\n          \n          \n          Bethesda, MD\n          U.S. National Library of Medicine\n          ClinicalTrials.gov\n          \n          2024"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/jpen.2286","article-title":"Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel","volume":"46","author":"Reiner","year":"2022","journal-title":"J Parenteral Enteral Nutr"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002801","article-title":"Efficacy and safety of liraglutide in patients with an ileal pouch-anal anastomosis and chronic high bowel frequency: a placebo-controlled, crossover, proof-of-concept study","volume":"119","author":"Herfarth","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0162","article-title":"Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease: real-world evidence in US adults","volume":"42","author":"Wang","year":"2019","journal-title":"Diabetes Care"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04339-w","article-title":"Repurposing liraglutide to the management of DSS-induced colitis: a potential for promoting autophagy","volume":"398","author":"Saadoun","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0413-7","article-title":"Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2","volume":"41","author":"Ning","year":"2020","journal-title":"Acta Pharmacol Sin"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1790420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T04:17:16Z","timestamp":1779077836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1790420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":121,"alternative-id":["10.3389\/fgstr.2026.1790420"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1790420","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"1790420"}}